FDA-Approved drug shows promise for Tough-to-Treat EoE with strictures
NCT ID NCT06352073
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well dupilumab, an already approved drug, works for people with severe eosinophilic esophagitis (EoE) that has caused narrowing of the esophagus. About 23 participants aged 16 and older will receive weekly injections of dupilumab for one year. The goal is to see if the drug can reduce inflammation and improve swallowing, potentially reducing the need for dilation procedures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ESOPHAGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States